Reneo Pharmaceuticals
Edit

Reneo Pharmaceuticals

http://www.reneopharma.com/
Last activity: 07.10.2024
Active
Categories: DevelopmentDrugEnergyTechLearnLifeLivingMedtechMovingProductionPublic
Moving Medicines to Move People Reneo is focused on improving the lives of patients with rare genetic mitochondrial diseases. Learn More Our priority is to develop therapies to improve daily function and quality of life of patients living with these rare diseases. Learn More Reneo’s lead product candidate, REN001, is known to control a number… Continue reading Home
Mentions
18
Location: United States, California, San Diego
Total raised: $145M
Email

Investors 5

Funding Rounds 2

DateSeriesAmountInvestors
11.01.2021Series B$95MAbingworth...
20.05.2019Series A$50MNew Enterp...

Mentions in press and media 18

DateTitleDescription
07.10.2024Business | Boulder’s OnKure goes public with merger; key drug trial underwayOnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a merger that takes OnKure public and injects $65 million into the company as it moves through a key trial for its leading bre...
13.11.2023Reneo Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTopline data results from the pivotal STRIDE study are expected in December 2023 IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the developmen...
31.03.2021Reneo Pharmaceuticals Files for $100M IPOReneo Pharmaceuticals, a clinical-stage pharmaceutical company, filed an initial public offering (IPO) to raise up to $100 million on March 19, which puts Reneo among life science companies to recently enter the public market. The Carmel Va...
11.01.2021Reneo Raises $95 Million for Rare Mitochondrial DiseaseLess than two years after launching its new venture with $50 million in the bank, Reneo Pharmaceuticals follows up in a $95M Series B to further its mission to treat diseases of the mitochondria... Take 1 minute to subscribe and you'll get ...
11.12.2020Reneo Pharmaceuticals Raises $95M in Series B FinancingReneo Pharmaceuticals, Inc., a San Diego, CA-based clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, raised $95m in Series B financing. The round was co-led by No...
11.12.2020­Reneo Pharmaceuticals Raises $95M in Series B FinancingReneo Pharmaceuticals, Inc., a San Diego, CA-based clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, raised $95m in Series B financing. The round was co-led by No...
11.12.2020New Enterprise Associates Join $95M Series B for Reneo PharmaceuticalsReneo Pharmaceuticals, Inc., a San Diego, CA-based clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, raised $95m in Series B financing. The round was co-led by No...
11.12.2020Reneo Pharmaceuticals Raises $95M in Series B FinancingReneo Pharmaceuticals, Inc., a San Diego, CA-based clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, raised $95m in Series B financing. The round was co-led by No...
11.12.2020New Enterprise Associates Join $95M Series B for Reneo PharmaceuticalsReneo Pharmaceuticals, Inc., a San Diego, CA-based clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, raised $95m in Series B financing. The round was co-led by No...
09.12.2020­Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and AbingworthSAN DIEGO, Dec. 9, 2020 /PRNewswire/ -- Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVes...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In